Giselle Sholler
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Giselle Sholler sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Giselle Sholler: 20 sponsored US clinical trials, 7 recruiting.
Giselle Sholler sponsors 20 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neuroblastoma, with 7 trials.
Top-decile sponsor footprint
Giselle Sholler ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (69.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
NCT06540963
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
NCT05489887
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
Beat Childhood Cancer Specimen Banking and Data Registry
NCT04715178
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Trial of Tolcapone With Oxaliplatin for Neuroblastoma
NCT02630043
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
NCT02395666
Molecular-Guided Therapy for Childhood Cancer
NCT02162732
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
NCT02139397
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
NCT01774253
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
NCT01802567
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
NCT01505608
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
NCT01483820
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
NCT01355679
A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma
NCT01109238
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
NCT01059071
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
NCT00867568
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
NCT00601003
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 9 |
Therapeutic Areas
What is open in the Giselle Sholler pipeline
7 recruiting of 20 indexed (35% open); 9 completed (45%).
Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Neuroblastoma (7 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Giselle Sholler: open-pipeline peers nationwide
Peers matched on 20 registered trials and 35% open enrollment, not the therapeutic-area sidebar.
Giselle Sholler sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 35% open enrollment (± trial volume)
- The Hospital for Sick Children · 35% recruiting · 23 trials
- Stemline Therapeutics · 35% recruiting · 17 trials
- Trustees of Dartmouth College · 35% recruiting · 31 trials
- The University of Texas at Arlington · 34% recruiting · 32 trials
Related
What to do with this Giselle Sholler page
20 registered trials is a research-attention snapshot, not an endorsement of Giselle Sholler or any single study.
- 7 of Giselle Sholler's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Neuroblastoma is the condition Giselle Sholler studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neuroblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Giselle Sholler pipeline card: 20 registered trials from official public datasets.Report a data error.